Role of Imaging-based Biomarkers in NAFLD: Recent Advances in Clinical Application and Future Research Directions

Overview

Journal J Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2017 Dec 6

PMID 29203392

Citations 45

Authors

Rohit Loomba

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a major public health problem afflicting approximately one billion individuals worldwide. Liver biopsy is considered the gold standard for assessment of liver disease severity in patients with NAFLD. However, it is invasive, has high inter-observer variability, and is associated with adverse effects, including pain, infection and, albeit rarely, death. It is also impractical because of the large number of individuals who have NAFLD. Therefore, tools to non-invasively assess disease severity in NAFLD are urgently needed. Over the last two decades, tremendous advances have been made in the assessment of NAFLD by non-invasive imaging. In this review, we will discuss the different non-invasive imaging modalities available to quantify liver fat and liver fibrosis. We will also discuss the limitations of current modalities to detect the progressive form for NAFLD, termed non-alcoholic steatohepatitis. Finally, we will discuss the comparative efficacy of various imaging-based elastographic modalities for detection of advanced fibrosis or cirrhosis, as well as their diagnostic characteristics.

Citing Articles

Sequential ultrasound molecular imaging for noninvasive identification and assessment of non-alcoholic steatohepatitis in mouse models.

Sha T, You Y, Miao X, Deng H, Zhang W, Ye H Liver Res. 2025; 7(4):342-351.

PMID: 39958780 PMC: 11791912. DOI: 10.1016/j.livres.2023.11.002.

Development of a Novel four-gene Model for Monitoring the Progression from Metabolic Dysfunction-associated Steatotic Liver Disease to Hepatocellular Carcinoma in Males.

Jiang Y, Chen J, Xu L, Lv L, Gan X J Cancer. 2025; 16(3):917-931.

PMID: 39781352 PMC: 11705051. DOI: 10.7150/jca.100724.

Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females.

Gan X, Zhou Y, Li Y, Xu L, Liu G Discov Oncol. 2024; 15(1):812.

PMID: 39699604 PMC: 11659565. DOI: 10.1007/s12672-024-01636-3.

Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus.

Ahmadizar F, Younossi Z J Clin Gastroenterol. 2024; 59(1):36-46.

PMID: 39352015 PMC: 11630663. DOI: 10.1097/MCG.0000000000002079.

Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis.

Azizi N, Naghibi H, Shakiba M, Morsali M, Zarei D, Abbastabar H Eur Radiol. 2024; .

PMID: 39254718 DOI: 10.1007/s00330-024-11001-1.

References

Szczepaniak L, Nurenberg P, Leonard D, Browning J, Reingold J, Grundy S . Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2004; 288(2):E462-8. DOI: 10.1152/ajpendo.00064.2004. View

Paige J, Bernstein G, Heba E, Costa E, Fereirra M, Wolfson T . A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease. AJR Am J Roentgenol. 2017; 208(5):W168-W177. PMC: 5512552. DOI: 10.2214/AJR.16.16726. View

Chen J, Yin M, Talwalkar J, Oudry J, Glaser K, Smyrk T . Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. Radiology. 2016; 283(2):418-428. PMC: 5395333. DOI: 10.1148/radiol.2016160685. View

Wong V, Wong G, Yeung D, Lau T, Chan C, Chim A . Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2014; 62(1):182-9. DOI: 10.1016/j.jhep.2014.08.041. View

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

Yokoo T, Serai S, Pirasteh A, Bashir M, Hamilton G, Hernando D . Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. Radiology. 2017; 286(2):486-498. PMC: 5813433. DOI: 10.1148/radiol.2017170550. View

Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T . Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol. 2005; 39(7):619-25. DOI: 10.1097/00004836-200508000-00012. View

Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day C . Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 2012; 32(8):1242-52. DOI: 10.1111/j.1478-3231.2012.02804.x. View

Schwenzer N, Springer F, Schraml C, Stefan N, Machann J, Schick F . Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009; 51(3):433-45. DOI: 10.1016/j.jhep.2009.05.023. View

10.

Pavlides M, Banerjee R, Tunnicliffe E, Kelly C, Collier J, Wang L . Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int. 2016; 37(7):1065-1073. PMC: 5518289. DOI: 10.1111/liv.13284. View

11.

de Ledinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart J, Cassinotto C . Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014; 60(5):1026-31. DOI: 10.1016/j.jhep.2013.12.018. View

12.

Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H . Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology. 2015; 150(3):626-637.e7. DOI: 10.1053/j.gastro.2015.11.048. View

13.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

14.

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

15.

de Moura Almeida A, Cotrim H, Barbosa D, de Athayde L, Santos A, Bitencourt A . Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol. 2008; 14(9):1415-8. PMC: 2693692. DOI: 10.3748/wjg.14.1415. View

16.

Palmeri M, Wang M, Rouze N, Abdelmalek M, Guy C, Moser B . Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol. 2011; 55(3):666-672. PMC: 3092839. DOI: 10.1016/j.jhep.2010.12.019. View

17.

Rockey D, Caldwell S, Goodman Z, Nelson R, Smith A . Liver biopsy. Hepatology. 2009; 49(3):1017-44. DOI: 10.1002/hep.22742. View

18.

Dulai P, Singh S, Patel J, Soni M, Prokop L, Younossi Z . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017; 65(5):1557-1565. PMC: 5397356. DOI: 10.1002/hep.29085. View

19.

Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A . Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2016; 9(5):692-701. PMC: 4984335. DOI: 10.1177/1756283X16656735. View

20.

Foucher J, Castera L, Bernard P, Adhoute X, Laharie D, Bertet J . Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006; 18(4):411-2. DOI: 10.1097/00042737-200604000-00015. View